Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Akihiro Hirakawa
Observed name:
AKIHIRO HIRAKAWA
Institution:
Institute of Science Tokyo
Observed institution:
Institute of Science Tokyo
ORCID:
0000-0002-1193-8104
Observed ORCID:
0000-0002-1193-8104
OpenAlex ID:
A5126360101
Clinical Features and Risk Factors of Enfortumab Vedotin–Induced Peripheral Neuropathy in Patients With Metastatic Urothelial Carcinoma: A Multicenter Retrospective Study ( YUSHIMA Study)
2025
·
Takahiko Soma
, Hajime Tanaka
, et al.
·
International Journal of Urology
·
7
PDF
Delayed Survival Benefit of Enzalutamide Plus Radium‐223 in Metastatic Castration‐Resistant Prostate Cancer: A Time‐Dependent Analysis of Reconstructed Individual Patient Data From the PEACE ‐3 Trial
2026
·
Wei Chen
, Soichiro Yoshida
, et al.
·
International Journal of Urology
·
4
PDF
Quantitative Assessment of Additive Effects of Mirabegron and Solifenacin in Overactive Bladder: Re-analysis of SYNERGY Study
2026
·
Wei Chen
, Soichiro Yoshida
, et al.
·
Urology
·
2
Mixture cure model analysis of event-free survival in the NIAGARA Trial: Quantifying the cure fraction benefit of perioperative durvalumab in muscle-invasive bladder cancer
2026
·
Shugo Yajima
, Soichiro Yoshida
, et al.
·
Urologic Oncology Seminars and Original Investigations
·
2
Bayesian Multi‐Criteria Decision Analysis of Net Clinical Benefit in ARASENS : Overall and Japanese Subgroup Results
2026
·
Kenji Tanabe
, Soichiro Yoshida
, et al.
·
International Journal of Urology
·
2
PDF
Bayesian Re‐Interpretation of the CheckMate ‐ 9ER Final Analysis: Organ‐Site and IMDC Risk‐Stratified Probabilities of Benefit
2026
·
Hiroshi Fukushima
, Shugo Yajima
, et al.
·
International Journal of Urology
·
2
PDF
Pharmacologic synergy versus independent action in androgen receptor-axis-targeted agent-docetaxel triplet therapy for metastatic hormone-sensitive prostate cancer: a copula-based analysis
2026
·
Wei Chen
, Soichiro Yoshida
, et al.
·
Urologic Oncology Seminars and Original Investigations
·
2
Bayesian Analysis to Refine East Asian Subgroup Estimates in the CLEAR Trial (Lenvatinib Plus Pembrolizumab vs . Sunitinib) for Advanced Renal Cell Carcinoma
2026
·
MOTOHIRO FUJIWARA
, SOICHIRO YOSHIDA
, et al.
·
Anticancer Research
·
1
Non‐Proportional Hazards Analysis of the RADIOSA Trial Using Reconstructed Individual Patient Data
2026
·
Kenji Tanabe
, Soichiro Yoshida
, et al.
·
International Journal of Urology
·
1
Bayesian Power Prior in Platform Trials With Non‐Concurrent Control for Binary Outcomes: Development and Comparative Evaluation
2026
·
Junichi Asano
, Hiroyuki Sato
, et al.
·
Statistics in Medicine
·
1
Complete Response Durability After TAR-200 and Nadofaragene Firadenovec in BCG-unresponsive Bladder CIS
2026
·
HIROSHI FUKUSHIMA
, SOICHIRO YOSHIDA
, et al.
·
Anticancer Research
Time-dependent effects of BCG plus immune checkpoint inhibitors in BCG-naive high-risk non-muscle-invasive bladder cancer: a reconstructed patient-level analysis
2026
·
Shugo Yajima
, Soichiro Yoshida
, et al.
·
International Urology and Nephrology
C-reactive protein at pembrolizumab initiation and its trajectory from first-line chemotherapy as prognostic markers in metastatic urothelial carcinoma (YUSHIMA study)
2026
·
Shugo Yajima
, Soichiro Yoshida
, et al.
·
International Urology and Nephrology
Bayesian re-analysis of ERA223 and PEACE-3 temporal dynamics and bone protection in radium-223-treated metastatic castration-resistant prostate cancer
2026
·
Wei Chen
, Soichiro Yoshida
, et al.
·
Japanese Journal of Clinical Oncology
Evolving Variants, Shifting Outcomes: Implications for Nonconcurrent Controls in Platform Trials for COVID ‐19
2026
·
Shin Watanabe
, Yosuke Shimizu
, et al.
·
Pharmaceutical Statistics
External validation of the Meet-URO score in Japanese metastatic renal cell carcinoma patients receiving first-line immune-combinations
2026
·
Shugo Yajima
, Soichiro Yoshida
, et al.
·
International Urology and Nephrology
Reanalysis of LUNAR progression-free survival using reconstructed individual patient data: time-varying treatment effects
2026
·
Kenji Tanabe
, Soichiro Yoshida
, et al.
·
International Urology and Nephrology
Show more works
View as search
Works count:
17
Citation count:
24
H-index:
2
I10-index:
Year
Topic
Type